Cardiff Oncology (NASDAQ:CRDF) & Elicio Therapeutics (NASDAQ:ELTX) Financial Analysis

Elicio Therapeutics (NASDAQ:ELTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Elicio Therapeutics and Cardiff Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1	1	4	0	2.50
Cardiff Oncology	1	4	2	0	2.14

Elicio Therapeutics presently has a consensus price target of $19.75, suggesting a potential upside of 535.05%. Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 746.41%. Given Cardiff Oncology’s higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Elicio Therapeutics.

Profitability

This table compares Elicio Therapeutics and Cardiff Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

Insider and Institutional Ownership

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 28.6% of Elicio Therapeutics shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Elicio Therapeutics and Cardiff Oncology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57 million	($2.17)	-1.43
Cardiff Oncology	$590,000.00	116.83	-$45.85 million	($0.60)	-1.48

Elicio Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Elicio Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Summary

Elicio Therapeutics beats Cardiff Oncology on 7 of the 13 factors compared between the two stocks.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.